Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma 1Myoepithelioma 1Liposarcoma, Myxoid 1Histiocytoma, Angiomatoid Fibrous 1Fibroma 1Desmoplastic Small Round Cell Tumor 1Chondrosarcoma, Extraskeletal Myxoid 1

Interventions

Cyclophosphamide 9Topotecan 5Temozolomide 5Melphalan 5Irinotecan 5Busulfan 5fludarabine 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4liposomal doxorubicin 3fludarabine phosphate 3cabozantinib 3Vincristine 3regorafenib 2pegfilgrastim 2Sirolimus 2Doxorubicin 2Bone Marrow Transplantation 2trioctyl phosphine oxide 1trifluridine tipiracil drug combination 1thymoglobulin 1talazoparib 1selinexor 1seclidemstat 1racotumomab 1poly ICLC 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1olaparib 1niraparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma, Ewing × seclidemstat × Clear all
NCT03600649 2023-11-21

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Salarius Pharmaceuticals, LLC

Phase 1 Unknown
50 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibroma, Myoepithelioma, Sarcoma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡